NASDAQ:RTRX
Delisted
Retrophin Stock News
$26.63
+0 (+0%)
At Close: Jul 20, 2022
Topline data from interim 36-week proteinuria endpoint on track for first quarter of 2021 Topline data from interim 36-week proteinuria endpoint on track for first quarter of 2021
Retrophin Completes Acquisition of Orphan Technologies
04:05pm, Thursday, 12'th Nov 2020
Addition of OT-58 strengthens pipeline of potential first-in-class therapies targeting rare diseases Addition of OT-58 strengthens pipeline of potential first-in-class therapies targeting rare disease
Retrophin to Present at Upcoming Investor Conferences
04:30pm, Wednesday, 11'th Nov 2020
SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will present at the following upcoming virtual investor conferences in November and
Retrophin's (RTRX) CEO Eric Dube on Q3 2020 Results - Earnings Call Transcript
11:07am, Sunday, 08'th Nov 2020
Retrophin's (RTRX) CEO Eric Dube on Q3 2020 Results - Earnings Call Transcript
Retrophin Reports Third Quarter 2020 Financial Results
04:01pm, Thursday, 05'th Nov 2020
Pivotal DUPLEX Study of sparsentan in FSGS nears completion of enrollment; topline proteinuria data expected 1Q21
